Can hyperbaric oxygenation decrease doxorubicin hepatotoxicity and improve regeneration in the injured liver?

Basit Öğe Kaydı
dc.contributor.authorFirat, Ozgur
dc.contributor.authorKirdok, Ozgur
dc.contributor.authorMakay, Ozer
dc.contributor.authorCaliskan, Cemil
dc.contributor.authorYilmaz, Funda
dc.contributor.authorIlgezdi, Savas
dc.contributor.authorKarabulut, Bulent
dc.contributor.authorCoker, Ahmet
dc.contributor.authorZeytunlu, Murat
dc.date.accessioned2019-10-27T20:52:09Z
dc.date.available2019-10-27T20:52:09Z
dc.date.issued2009
dc.departmentEge Üniversitesien_US
dc.description.abstractPortal vein embolization is used in the treatment of hepatocellular cancer, with the purpose of enhancing resectability. However, regeneration is restricted due to hepatocellular injury following chemotherapeutics (e.g. doxorubicin). The aim of this study was to investigate whether hyperbaric oxygenation (HBO) can alleviate the hepatotoxicity of chemotherapy and improve regeneration in the injured liver. Rats were allocated to four experimental groups. Group I rats were subjected to right portal vein ligation (RPVL); rats in groups II and III were administered doxorubicin prior to RPVL, with group III rats being additionally exposed to HBO sessions postoperatively; group IV rats was sham-operated. All rats were sacrificed on postoperative day 7, and liver injury was assessed by measuring alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. Protein synthetic ability was determined based albumin levels and liver regeneration by the mitotic index (MI). The AST and ALT values of group II rats were significantly higher than those of group I, but not those of group III. Rats treated with doxorubicin and HBO (groups II and III) showed slightly but not significant differences in albumin levels than those subjected to only RPVL or sham-operated. The MI was significantly increased in groups I, II, and III, with the MI of group III rats significantly higher than those of group I rats. Based on our results, we conclude that HBO treatment has the potential to diminish doxorubicin-related hepatotoxicity and improve regeneration in the injured liver.en_US
dc.identifier.doi10.1007/s00534-009-0059-9en_US
dc.identifier.endpage352en_US
dc.identifier.issn0944-1166
dc.identifier.issn1436-0691
dc.identifier.issue3en_US
dc.identifier.pmid19288285en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage346en_US
dc.identifier.urihttps://doi.org/10.1007/s00534-009-0059-9
dc.identifier.urihttps://hdl.handle.net/11454/43196
dc.identifier.volume16en_US
dc.identifier.wosWOS:000265566800019en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer Japan Kken_US
dc.relation.ispartofJournal of Hepato-Biliary-Pancreatic Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDoxorubicinen_US
dc.subjectHyperbaric oxygenationen_US
dc.subjectPortal vein embolizationen_US
dc.titleCan hyperbaric oxygenation decrease doxorubicin hepatotoxicity and improve regeneration in the injured liver?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu